Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyHealth Net Duobrii Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentHealth NetPolicy CP PMN.208

    Duobrii (halobetasol propionate/tazarotene) topical lotion — coverage criteria

    Customize your policy alerts

    Sign up for Health Net Policy CP PMN.208 alerts

    Get alerted when Policy CP PMN.208 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governs medical necessity criteria, prior authorization, and coverage limits for Duobrii topical lotion for plaque psoriasis in adults across Health Net lines of business covered by this policy.

    Policy Summary
    PayerHealth Net
    PolicyDuobrii (halobetasol propionate/tazarotene) topical lotion — coverage criteria
    Policy CodePolicy CP PMN.208
    Change TypeStep therapy bypass added for Illinois HIM
    Effective Date
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Step therapy bypass for Illinois HIM per IL HB 5395 was added (step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026).

    100 g

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    maximum supply per month
    12 moapproval duration
    ≥18minimum age
    Plaque psoriasisFDA-approved indication
    50 g/wkcomparator dosing alt max

    Coverage Criteria

    Initial Therapy

    Covered when ALL of the following are met for initial approval:

    Initial Approval Criteria: 1) Diagnosis of plaque psoriasis with body surface area involvement ≥ 20%; 2) Age ≥ 18 years; 3) Prescribed by or in consultation with a dermatologist or rheumatologist; 4) Failure of generic halobetasol propionate and generic clobetasol propionate unless both are contraindicated or clinically significant adverse effects are experienced (step therapy requirements do not apply for Illinois HIM requests as of 1/1/2026 per IL HB 5395); 5) Failure of generic tazarotene unless contraindicated or clinically significant adverse effects are experienced (step therapy requirement does not apply for Illinois HIM requests as of 1/1/2026 per IL HB 5395); 6) Dose does not exceed 100 g per month (one tube per month).

    Approval duration: 12 months

    Continuation Therapy

    Covered for continued therapy when ALL of the following are met:

    Continued Therapy Criteria: 1) Member is currently receiving medication via the benefit or has previously met initial approval criteria (continuity of care provisions may apply); 2) Member is responding positively to therapy; 3) If request is for a dose increase, the new dose does not exceed 100 g per month (one tube per month).

    Approval duration: 12 months

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the referenced off‑label use policies (for example, CP.CPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, and CP PMN.53 for Medicaid) or other applicable evidence of coverage documentation.

    Use of this product is contraindicated in pregnancy. Providers should not initiate therapy in pregnant patients and must document pregnancy status when relevant to coverage decisions.

    Requests for use outside the FDA‑approved indication require submission of supporting clinical documentation. If the request does not include adequate evidence of efficacy and safety per the applicable off‑label use policy (see CP.CPA.09, HIM.PA.154, CP PMN.53), the request will be considered not authorized / medical necessity not met.

    Coding and Limits

    Policy identifiermixed
    CP PMN.208Policy reference number (document identifier)
    Coding thresholds
    Maximum supply per month100 g per month (one 100 g tube)
    Equivalent weekly maximum noted for dosing guidance50 g per week (appendix dosing table)
    Product packagingAvailable as 100 g tubes

    Provider Actions / Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Provider must submit documentation (such as office chart notes, lab results, or other clinical information) supporting that the member has met all initial approval criteria for coverage.

    • Approval duration: 12 months
    • Dose limit: does not exceed 100 g per month (one tube per month)
    Step Therapy

    Step Therapy (IL HIM Bypass)

    Step therapy requirements apply for initial approval: members must have failed specified generic topical agents (e.g., halobetasol propionate and clobetasol propionate, and tazarotene) unless these agents are contraindicated or cause clinically significant adverse effects. For Illinois HIM requests only, the step therapy requirements do not apply as of 2026-01-01 per IL HB 5395 — providers should note the operational bypass for HIM members.

    • Step therapy failures required unless contraindicated or adverse effects documented
    • Illinois HIM bypass effective 2026-01-01 per IL HB 5395

    Drug Definitions and Comparators

    Product definition
    DrugDuobrii (halobetasol propionate 0.01% / tazarotene 0.045% lotion)
    ComponentsHalobetasol propionate 0.01% (high‑potency corticosteroid) and tazarotene 0.045% (retinoid)
    FDA‑approved indicationTopical treatment of plaque psoriasis (PsO) in adults
    Dosing summaryApply a thin layer once daily to affected areas until control is achieved; dosing guidance lists 50 g/week as an appendix maximum
    Therapeutic alternatives
    Halobetasol alternatives (high‑potency corticosteroids)Ultravate (halobetasol propionate 0.05% cream/ointment) — dosing: apply thin layer QD–BID; treatment generally limited; maximum dose listed as 50 g/week

    Background

    Duobrii lotion is a fixed‑dose topical combination containing halobetasol propionate (a high‑potency corticosteroid) and tazarotene (a topical retinoid). It is indicated for the topical treatment of plaque psoriasis in adults and is supplied as a 100 g tube. Typical administration is once‑daily application of a thin layer to affected areas until control is achieved; dosing guidance in this policy limits total use to no more than 100 g per month (one 100 g tube).

    Policy Summary
    PayerHealth Net
    PolicyDuobrii (halobetasol propionate/tazarotene) topical lotion — coverage criteria
    Policy CodePolicy CP PMN.208
    Change TypeStep therapy bypass added for Illinois HIM
    Effective Date
    Next Review Date
    Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria for prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and LimitsProvider Actions / Prior AuthorizationDrug Definitions and ComparatorsBackground
    Documentation Required

    Required Documentation

    Provider must submit supporting clinical documentation with the prior authorization request. Acceptable documentation includes office/chart notes, relevant lab results, consultation notes, and any other clinical information demonstrating the member meets all listed criteria.

    • Include documentation of step therapy trials or reason for bypass (e.g., contraindication, adverse effects)
    • Include documentation of diagnosis, body surface area involvement, prescribing clinician specialty (dermatologist or rheumatologist), and dosing
    Denial Risk

    Documentation/Indication Not Supported — Denial Risk

    Requests lacking required documentation or requests for non‑covered/unapproved indications may be denied. If the indication is non‑FDA approved, provide sufficient evidence of efficacy and safety per applicable off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for HIM, CP PMN.53 for Medicaid) or applicable evidence of coverage documents.

    • Denial risk if documentation of step therapy trials, contraindications, or diagnosis severity (BSA) is missing
    • Non‑FDA approved indications require supporting evidence per listed off‑label policies
    Clobetasol alternativeClobex (clobetasol propionate 0.05% formulations) — dosing: apply thin layer BID; treatment limits noted; maximum dose listed as 50 g/week
    Bryhali (halobetasol)Halobetasol propionate 0.01% lotion (Bryhali) — apply once daily; maximum dose listed as 50 g/week
    Tazarotene alternativeTazorac (tazarotene cream/gel) — apply a thin layer once daily; typical max dose listed as 2 mg/cm²/day (per appendix dosing table)